The FDA Reauthorization Act of 2017 primarily:

• A. Repeals all drug user fees.
• B. Amends the FD&C Act to extend drug user fee authority through 2022.
• C. Eliminates the CDER.
• D. Creates new drug labeling requirements.

Answer: (B)

The main idea here is funding and timeliness for FDA reviews. The FDA Reauthorization Act of 2017 is primarily about reauthorizing the user fee programs that fund the agency’s drug review work, and it sets performance goals for how quickly those reviews should be completed. This act extends the authority to collect drug, generic drug, and certain related user fees through 2022, ensuring continued staffing and resources for CDER to evaluate new products while maintaining safety standards. It’s not about repealing fees, eliminating CDER, or adding new labeling rules. Those elements aren’t the focus of this reauthorization, which centers on funding and efficient review timelines.